Evidence map›Paper›PMID 34092127›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2021

Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.

Qian Zhong, Ying Xiong, Chen Ling, Yanping Qian, Xia Zhao, Hanshuo Yang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. The dual role of microRNA (miR)-20b in cancers: Friend or foe?Cell communication and signaling : CCS · 2023
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Qian ZhongDepartment of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, P.R. China.ORCID 0000-0001-8354-5839
Ying XiongDepartment of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, P.R. China.
Chen LingDepartment of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, P.R. China.
Yanping QianDepartment of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, P.R. China.
Xia ZhaoDepartment of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, P.R. China.
Hanshuo YangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported that cyclin D1 silencing interferes with RAD51 accumulation and increases the sensitivity of BRCA1 wild-type ovarian cancer cells to olaparib. However, the mechanisms associated with cyclin D1 overexpression in ovarian cancer are not fully understood. TargetScan predicted the potential binding sites for microRNA-20b (miR-20b) and the 3'-untranslated region of cyclin D1 mRNA; thus, we used luciferase reporter assay to verify those binding sites. The Kaplan-Meier method and log-rank test were used to examine the relationship between miR-20b and progression-free survival of ovarian cancer patients in The Cancer Genome Atlas (

Indexed as

3' Untranslated RegionsAnimalsAntineoplastic AgentsCell Cycle CheckpointsCell Line, TumorCyclin D1Disease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB CMicroRNAsOvarian NeoplasmsPhthalazinesPiperazines3' Untranslated RegionsAntineoplastic AgentsCCND1 protein, humanCyclin D1MicroRNAsMIRN20b microRNA, humanolaparibPhthalazinesPiperazinescyclin D1microRNA-20bolaparibOvarian cancerprognosis

Identifiers

PMID34092127
PMCPMC8371305
OpenAlexW3171986436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.